Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

被引：0
|
作者：
Austin Lammers
Ruibin Wang
Jeremy Cetnar
Vinay Prasad
机构：
[1] Oregon Health & Science University,Division of Hematology Oncology, Knight Cancer Institute
[2] Johns Hopkins Bloomberg School of Public Health,Department of Epidemiology
[3] Oregon Health & Science University,Department of Public Health and Preventive Medicine
[4] Oregon Health & Science University,Center for Health Care Ethics
来源：
Blood Cancer Journal | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation
    DeLoughery, E. P.
    Prasad, V.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 527 - 529
  • [22] Participation of African American Persons in Clinical Trials Supporting US Food and Drug Administration Approval of Cancer Drugs
    Al Hadidi, Samer
    Mims, Martha
    Miller-Chism, Courtney Nicole
    Kamble, Rammurti
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (04) : 320 - +
  • [23] Comparison of drug approval between health Canada (HC) and the US Food and Drug Administration (FDA).
    Ezeife, Doreen Anuli
    Tang, Patricia
    Heng, Daniel Yick Chin
    Welch, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Comments on "The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020"
    Jakobsen, Anders K. M.
    Spindler, Karen-Lise Garm
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (07) : 1423 - 1424
  • [25] Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
    Sachs, Rachel E.
    Gavulic, Kyle A.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    JAMA HEALTH FORUM, 2021, 2 (10): : E213177
  • [26] Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
    Naci, Huseyin
    Smalley, Katelyn R.
    Kesselheim, Aaron S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (07): : 626 - 636
  • [27] Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs
    Naci, Huseyin
    Guan, Xiaodong
    Woloshin, Steven
    Xu, Ziyue
    Wagner, Anita K.
    JAMA INTERNAL MEDICINE, 2021, 181 (11) : 1521 - 1522
  • [28] Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer
    Yamashita, Kenji
    Kaneko, Masayuki
    Narukawa, Mamoru
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (09) : 1193 - 1200
  • [29] Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
    Michaeli, Thomas
    Michaeli, Daniel Tobias
    VALUE IN HEALTH, 2024, 27 (04) : 449 - 457
  • [30] Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer
    Kenji Yamashita
    Masayuki Kaneko
    Mamoru Narukawa
    European Journal of Clinical Pharmacology, 2019, 75 : 1193 - 1200
12345